Suppr超能文献

原发性硬化性胆管炎的发病机制及诊治进展。

Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.

机构信息

Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.

出版信息

Gastroenterology. 2013 Sep;145(3):521-36. doi: 10.1053/j.gastro.2013.06.052. Epub 2013 Jul 1.

Abstract

Primary sclerosing cholangitis (PSC), first described in the mid-1850s, is a complex liver disease that is heterogeneous in its presentation. PSC is characterized by chronic cholestasis associated with chronic inflammation of the biliary epithelium, resulting in multifocal bile duct strictures that can affect the entire biliary tree. Chronic inflammation leads to fibrosis involving the hepatic parenchyma and biliary tree, which can lead to cirrhosis and malignancy. The etiology of PSC is not fully understood, which in part explains the lack of effective medical therapy for this condition. However, we have begun to better understand the molecular pathogenesis of PSC. The recognition of specific clinical subtypes and their pattern of progression could improve phenotypic and genotypic classification of the disease. We review our current understanding of this enigmatic disorder and discuss important topics for future studies.

摘要

原发性硬化性胆管炎(PSC)于 19 世纪 50 年代中期首次描述,是一种复杂的肝脏疾病,其表现具有异质性。PSC 的特征是慢性胆汁淤积,伴有胆管上皮的慢性炎症,导致多灶性胆管狭窄,可影响整个胆道树。慢性炎症导致肝实质和胆管纤维化,可导致肝硬化和恶性肿瘤。PSC 的病因尚未完全阐明,这在一定程度上解释了为什么对此病缺乏有效的医学治疗。然而,我们已经开始更好地了解 PSC 的分子发病机制。对特定临床亚型及其进展模式的认识可以改善疾病的表型和基因型分类。我们回顾了对这种神秘疾病的现有认识,并讨论了未来研究的重要课题。

相似文献

1
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.
Gastroenterology. 2013 Sep;145(3):521-36. doi: 10.1053/j.gastro.2013.06.052. Epub 2013 Jul 1.
2
Primary sclerosing cholangitis: diagnosis, prognosis, and management.
Clin Gastroenterol Hepatol. 2013 Aug;11(8):898-907. doi: 10.1016/j.cgh.2013.02.016. Epub 2013 Feb 27.
3
Primary sclerosing cholangitis.
Can J Gastroenterol. 2008 Aug;22(8):689-98. doi: 10.1155/2008/824168.
4
Imaging Features of Primary Sclerosing Cholangitis: From Diagnosis to Liver Transplant Follow-up.
Radiographics. 2019 Nov-Dec;39(7):1938-1964. doi: 10.1148/rg.2019180213. Epub 2019 Oct 18.
5
Recent insights in primary sclerosing cholangitis.
J Dig Dis. 2012 Jul;13(7):337-41. doi: 10.1111/j.1751-2980.2012.00605.x.
6
Primary sclerosing cholangitis.
Recent Results Cancer Res. 2011;185:117-33. doi: 10.1007/978-3-642-03503-6_7.
9
Cancer Risk and Surveillance in Primary Sclerosing Cholangitis.
Clin Liver Dis. 2016 Feb;20(1):79-98. doi: 10.1016/j.cld.2015.08.014. Epub 2015 Oct 21.
10
Chronic cholestatic diseases.
J Hepatol. 2000;32(1 Suppl):129-40. doi: 10.1016/s0168-8278(00)80421-3.

引用本文的文献

2
Autoimmune Diseases: Molecular Pathogenesis and Therapeutic Targets.
MedComm (2020). 2025 Jun 16;6(7):e70262. doi: 10.1002/mco2.70262. eCollection 2025 Jul.
3
The 2024 diagnostic criteria for primary sclerosing cholangitis.
J Gastroenterol. 2025 Jun 12. doi: 10.1007/s00535-025-02265-5.
4
Autoimmune liver diseases and systemic rheumatic disorders: exploring their interplay and impact on prognosis.
BMC Gastroenterol. 2025 Apr 22;25(1):282. doi: 10.1186/s12876-025-03852-9.
6
Deep Learning-Based Prediction of Hepatic Decompensation in Patients With Primary Sclerosing Cholangitis With Computed Tomography.
Mayo Clin Proc Digit Health. 2024 Jul 31;2(3):470-476. doi: 10.1016/j.mcpdig.2024.07.002. eCollection 2024 Sep.
7
Cholecystectomy Is Linked to Worse Clinical Outcomes in Primary Sclerosing Cholangitis.
Cureus. 2025 Mar 6;17(3):e80184. doi: 10.7759/cureus.80184. eCollection 2025 Mar.
10
Liver diseases: epidemiology, causes, trends and predictions.
Signal Transduct Target Ther. 2025 Feb 5;10(1):33. doi: 10.1038/s41392-024-02072-z.

本文引用的文献

3
Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis.
Hepatology. 2013 Sep;58(3):1084-93. doi: 10.1002/hep.26447. Epub 2013 Jul 30.
4
Inflammatory bowel disease in primary sclerosing cholangitis: a robust yet changing relationship.
Inflamm Bowel Dis. 2013 Apr;19(5):1004-9. doi: 10.1097/MIB.0b013e3182802893.
5
8
Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Clin Res Hepatol Gastroenterol. 2012 Sep;36 Suppl 1:S3-12. doi: 10.1016/S2210-7401(12)70015-3.
9
Risk factors for complications of ERCP in primary sclerosing cholangitis.
Endoscopy. 2012 Dec;44(12):1133-8. doi: 10.1055/s-0032-1325677. Epub 2012 Oct 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验